DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for junctional epidermolysis bullosa — screening already-approved drugs against its 8-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleJunctional epidermolysis bullosa maps to a 8-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for junctional epidermolysis bullosa is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
galactokinase 1 (GALK1) — GALK1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7RCM · 2.1 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Junctional epidermolysis bullosa is a severe genetic skin disease originating at the epidermal-dermal junction, characterised by structural and mechanical fragility of the integuments that leads to epidermal loss. As of 2021, there was no established cure. A 2021 report described long-term outcomes in a single child with a devastating form of junctional epidermolysis bullosa who had been treated with genetically corrected autologous epidermal cultures that regenerated almost an entire, fully functional epidermis. The report was funded by POR FESR 2014-2020 - Regione Emilia-Romagna and others, but the abstract gives no concrete numbers on survival, response rates, or sample size beyond that single patient.
Earlier attempts at treatment include a 2009 report of grafting cultured allogeneic keratinocytes to an infant with junctional epidermolysis bullosa letalis type Herlitz Pearson, a life-threatening disease for which effective therapy was lacking. The authors stated that any therapy improving wound healing would be beneficial, but the abstract provides no outcome data, survival figures, or response rates for that infant. A 1988 review described the structural features of the basement membrane and associated components that may be involved in pathogenesis, but offered no treatment results.
A 1992 review noted that linkage had recently been established between major forms of epidermolysis bullosa and mutations in genes encoding structural proteins, and predicted that this would improve diagnosis, including prenatal testing, and lead to new treatment approaches. However, nearly three decades later, the only long-term outcome data available still comes from a single patient treated with genetically corrected autologous cultures. What is still missing is evidence from larger trials, adequate funding to move beyond single-patient reports, and patient stratification to determine which genetic subtypes might respond to which approach.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Dermatology · 1988 · 60 citations
The basement membrane. Interface between the epithelium and the dermis: structural features
AbstractEpidermolysis bullosa is a disease originating at or close to the epidermal-dermal junction. The structural features of this interface are reviewed in detail, with particular emphasis on the basement membrane and associated intracellular and extracellular components that may be involved in the pathogenesis of various forms of epidermolysis bullosa.
New England Journal of Medicine · 2021 · 58 citations · open access
Transgenic Epidermal Cultures for Junctional Epidermolysis Bullosa — 5-Year Outcomes
AbstractInherited junctional epidermolysis bullosa is a severe genetic skin disease that leads to epidermal loss caused by structural and mechanical fragility of the integuments. There is no established cure for junctional epidermolysis bullosa. We previously reported that genetically corrected autologous epidermal cultures regenerated almost an entire, fully functional epidermis on a child who had a devastating form of junctional epidermolysis bullosa. We now report long-term clinical outcomes in this patient. (Funded by POR FESR 2014-2020 - Regione Emilia-Romagna and others.).
Treatment of Epidermolysis bullosa with Human Cultured Epidermal Allografts
AbstractJunctional epidermolysis bullosa letalis type Herlitz Pearson is a genetically determined, life-threatening disease. Effective therapy has been lacking to date. Therefore any therapy that improves wound healing would be beneficial for these patients. Cultured epidermal grafts are known to enhance wound epithelialization and have been used with success in some epidermolysis bullosa disorders. Encouraged by these reports, we grafted cultured allogeneic keratinocytes to an infant with a junctional epidermolysis bullosa letalis type.
AbstractDuring the past few years various proteins have come to the forefront as underlying the structural abnormalities of different forms of epidermolysis bullosa. Only very recently has linkage been established between certain major forms of epidermolysis bullosa and the genes encoding some of these proteins, and mutations of these genes identified. The stage will soon be set for providing a new and rational basis for a better understanding of the pathogenesis of epidermolysis bullosa, for improving diagnosis, including prenatal testing, and for devising new approaches to treatment.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
